ImClone Systems Inc (formerly IMCL)

[yaya704]

and is it possible to compare erbitux in either the flex study or the study below in the phase II setting to gauge how the two treatments compare to each other. or is it too early to have any comparisons on efficacy?

and how can imclone state that the study below has a completion date of Nov. 2006:



Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

This study is currently recruiting patients.
Verified by ImClone Systems August 2006

Sponsored by: ImClone Systems
Information provided by: ImClone Systems
ClinicalTrials.gov Identifier: NCT00095199


Purpose

This trial is a multicenter, open-label, randomized, phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will be randomized to one of the following 4 treatment arms: Cetuximab plus Docetaxel, Cetuximab plus Pemetrexed, Docetaxel alone, or Pemetrexed alone.
Condition Intervention Phase
Non-Small-Cell Lung Cancer
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cetuximab
Phase III


MedlinePlus related topics: Lung Cancer


Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy

Further study details as provided by ImClone Systems:

Expected Total Enrollment: 800
Study start: October 2004; Expected completion: November 2006